The state of Kansas currently has 172 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Wichita, Kansas City, Overland Park and Topeka.
Efficacy of Point Of Service Testing in MBC
Recruiting
This study will assess the efficacy of an innovative point of service cancer genetics counseling delivery model for metastatic breast cancer (MBC) patients whom have received a referral for hereditary cancer genetic counseling and testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/21/2023
Locations: The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas
Conditions: Metastatic Cancer, Breast Cancer
Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis
Recruiting
The purpose of this trial is to compare the morbidity and mortality of CRS-HIPEC using mitomycin-C versus melphalan for colorectal peritoneal carcinomatosis. Morbidity and mortality will measured using the Comprehensive Complication Index (CCI) score, Common terminology criteria for adverse events (CTCAE version 4.03), and the Clavien-Dindo Classification.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/07/2023
Locations: The University of Kansas Medical Center, Westwood, Kansas
Conditions: Cancer, Appendiceal, ColoRectal Cancer
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
Recruiting
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
Gender:
ALL
Ages:
All
Trial Updated:
05/08/2023
Locations: Hays Medical Center Dreiling-Schmidt Cancer Institute, Hays, Kansas +6 locations
Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
Recruiting
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2023
Locations: The University of Kansas Clinical Research Center, Fairway, Kansas +3 locations
Conditions: Breast Cancer